Intravenous iron and SGLT2 inhibitors in iron ‐deficient patients with heart failure and reduced ejection fraction

ConclusionsIn the IRONMAN trial, there was a trend to a greater increase in haemoglobin with ferric derisomaltose in iron-deficient patients taking an SGLT2 inhibitor at baseline, as compared with those not taking one.

https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14742?af=R

Source: ESC Heart Failure - March 29, 2024 Category: Cardiology Authors: Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, John G.F. Cleland, Ninian N. Lang, Mark C. Petrie, Michele Robertson, Ian Ford Tags: Original Article Source Type: research